基于证据的精准肿瘤学与癌症靶点组学
Evidence-Based Precision Oncology with the Cancer Targetome.
作者信息
Blucher Aurora S, Choonoo Gabrielle, Kulesz-Martin Molly, Wu Guanming, McWeeney Shannon K
机构信息
Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR, USA.
Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR, USA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
出版信息
Trends Pharmacol Sci. 2017 Dec;38(12):1085-1099. doi: 10.1016/j.tips.2017.08.006. Epub 2017 Sep 27.
A core tenet of precision oncology is the rational choice of drugs to interact with patient-specific biological targets of interest, but it is currently difficult for researchers to obtain consistent and well-supported target information for pharmaceutical drugs. We review current drug-target interaction resources and critically assess how supporting evidence is handled. We introduce the concept of a unified Cancer Targetome to aggregate drug-target interactions in an evidence-based framework. We discuss current unmet needs and the implications for evidence-based clinical omics. The focus of this review is precision oncology but the discussion is highly relevant to targeted therapies in any area.
精准肿瘤学的一个核心原则是合理选择药物，使其与患者特定的感兴趣的生物学靶点相互作用，但目前研究人员很难获得关于药物的一致且有充分支持的靶点信息。我们回顾了当前的药物-靶点相互作用资源，并严格评估了支持证据的处理方式。我们引入了统一癌症靶点组的概念，以便在基于证据的框架中汇总药物-靶点相互作用。我们讨论了当前未满足的需求以及对基于证据的临床组学的影响。本综述的重点是精准肿瘤学，但讨论内容与任何领域的靶向治疗都高度相关。
Zotero 插件